The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Unexpected Effect of Proton Pump Inhibitors: Elevation of the Cardiovascular Risk Factor Asymmetric Dimethylarginine
Open accessAbstract
Background—: Proton pump inhibitors (PPIs) are gastric acid–suppressing agents widely prescribed for the treatment of gastroesophageal reflux disease. Recently, several studies in patients with acute coronary syndrome have raised the concern that use of PPIs in these patients may increase their risk of major adverse cardiovascular events. The mechanism of this possible adverse effect is not known. Whether the general population might also be at risk has not been addressed. Methods and Results—: Plasma asymmetrical dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase. Elevated plasma ADMA is associated with increased risk for cardiovascular disease, likely because of its attenuation of the vasoprotective effects of endothelial nitric oxide synthase. We find that PPIs elevate plasma ADMA levels and reduce nitric oxide levels and endothelium-dependent vasodilation in a murine model and ex vivo human tissues. PPIs increase ADMA because they bind to and inhibit dimethylarginine dimethylaminohydrolase, the enzyme that degrades ADMA. Conclusions—: We present a plausible biological mechanism to explain the association of PPIs with increased major adverse cardiovascular events in patients with unstable coronary syndromes. Of concern, this adverse mechanism is also likely to extend to the general population using PPIs. This finding compels additional clinical investigations and pharmacovigilance directed toward understanding the cardiovascular risk associated with the use of the PPIs in the general population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress
Cai, H., & Harrison, D. G. (2000) · Circulation Research · doi:10.1161/01.res.87.10.840 · Cited by 3,839 · cited 1×
“ment of eNOS is associated with an increase in oxidative stress and a dysregulation of vasomotor tone.(55) Furthermore, given the anti-inflammatory and antiplatelet effects of endotheliumderived NO,(56,57) the impairment of eNOS would be anticipated to increase the risk of MACEs, as suggested by studies of coronary an…”
Schächinger, V., Britten, M. B., & Zeiher, A. M. (2000) · Circulation · doi:10.1161/01.cir.101.16.1899 · Cited by 2,585
HMEC-1: Establishment of an Immortalized Human Microvascular Endothelial Cell Line
Ades, E. W., Candal, F. J., Swerlick, R. A., George, V. G., Summers, S., Bosse, D. C., & Lawley, T. J. (1992) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12613748 · Cited by 1,265
Zoccali, C., Bode-Böger, S. M., Mallamaci, F., Benedetto, F. A., Tripepi, G., Malatino, L. S., Cataliotti, A., Bellanuova, I., Fermo, I., Frölich, J. C., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07217-8 · Cited by 1,087
Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin
Gilard, M., Arnaud, B., Cornily, J.-C., Le Gal, G., Lacut, K., Le Calvez, G., Mansourati, J., Mottier, D., Abgrall, J.-F., & Boschat, J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.06.064 · Cited by 1,015
Ho, P. M. (2009) · JAMA · doi:10.1001/jama.2009.261 · Cited by 1,007
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel
Juurlink, D. N., Gomes, T., Ko, D. T., Szmitko, P. E., Austin, P. C., Tu, J. V., Henry, D. A., Kopp, A., & Mamdani, M. M. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.082001 · Cited by 766
Homocysteine Impairs the Nitric Oxide Synthase Pathway: Role of Asymmetric Dimethylarginine
Stühlinger, M. C., Tsao, P. S., Her, J.-H., Kimoto, M., Balint, R. F., & Cooke, J. P. (2001) · Circulation · doi:10.1161/hc4601.098514 · Cited by 662
Self-citationLi, X.-Q., Andersson, T. B., Ahlström, M., & Weidolf, L. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.8.821 · Cited by 644
Böger, R. H., Sydow, K., Borlak, J., Thum, T., Lenzen, H., Schubert, B., Tsikas, D., & Bode-Böger, S. M. (2000) · Circulation Research · doi:10.1161/01.res.87.2.99 · Cited by 479
Cited by
Endothelial dysfunction and vascular disease - a 30th anniversary update
Vanhoutte, P. M., Shimokawa, H., Feletou, M., & Tang, E. H. C. (2017) · Acta Physiologica · doi:10.1111/apha.12646 · Cited by 937
“2); its production is accelerated by oxidative stress (Vallance and Leiper 2004, Wilcox 2012, Sasser et al. 2014) and proton pump inhibitors (Ghebremariam et al. 2013).”
BackgroundInfluentialFreedberg, D. E., Kim, L. S., & Yang, Y.-X. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.031 · Cited by 891
Strategies to increase nitric oxide signalling in cardiovascular disease
Lundberg, J. O., Gladwin, M. T., & Weitzberg, E. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4623 · Cited by 576
Moayyedi, P., Eikelboom, J. W., Bosch, J., Connolly, S. J., Dyal, L., Shestakovska, O., Leong, D., Anand, S. S., Störk, S., Branch, K. R. H., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.05.056 · Cited by 483
Complications of Proton Pump Inhibitor Therapy
Vaezi, M. F., Yang, Y.-X., & Howden, C. W. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.04.047 · Cited by 482
Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population
Shah, N. H., LePendu, P., Bauer-Mehren, A., Ghebremariam, Y. T., Iyer, S. V., Marcus, J., Nead, K. T., Cooke, J. P., & Leeper, N. J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0124653 · Cited by 335
Self-citationProton-pump inhibitors: understanding the complications and risks
Malfertheiner, P., Kandulski, A., & Venerito, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.117 · Cited by 297
Blood Pressure–Lowering Effect of Orally Ingested Nitrite Is Abolished by a Proton Pump Inhibitor
Montenegro, M. F., Sundqvist, M. L., Larsen, F. J., Zhuge, Z., Carlström, M., Weitzberg, E., & Lundberg, J. O. (2017) · Hypertension · doi:10.1161/hypertensionaha.116.08081 · Cited by 102
Nitric oxide deficiency is a primary driver of hypertension
Bryan, N. S. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115325 · Cited by 77
Pinheiro, L. C., Amaral, J. H., & Tanus-Santos, J. E. (2014) · Circulation · doi:10.1161/circulationaha.113.005307 · Cited by 8
Basaqr, R., & Babateen, A. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1648219 · Cited by 4
Metadata
- Authors
- Ghebremariam, Y. T., LePendu, P., Lee, J. C., Erlanson, D. A., Slaviero, A., Shah, N. H., Leiper, J., & Cooke, J. P.
- Venue
- Circulation
- Published
- 2013-08-20
- Volume
- 128
- Issue
- 8
- Pages
- 845-853
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2302382872
- Cited by
- 255
- References
- 59
- FWCI
- 11.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.